Long-Term Safety of Lu AF35700 for Adults With Schizophrenia
About this title
Read the official source — NCT02892422Researchers studied Lu AF35700, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
Understand this study
What did researchers investigate?
Researchers studied Lu AF35700, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Bellflower and 101 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 528
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Bulgaria, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT02892422
- Official title
Show the full official title
Interventional, Open-label, Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Bellflower, United States · Costa Mesa, United States · Culver City, United States
74 more locations
- Escondido, United States
- Garden Grove, United States
- National City, United States
- Oceanside, United States
- Orange, United States
- San Bernardino, United States
- Torrance, United States
- Lauderhill, United States
- Miami, United States
- North Miami, United States
- Oakland Park, United States
- Atlanta, United States
- Chicago, United States
- Hoffman Estates, United States
- Shreveport, United States
- Flowood, United States
- Las Vegas, United States
- Berlin, United States
- Fresh Meadows, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Charlotte, United States
- Norristown, United States
- Austin, United States
- Dallas, United States
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Lovech, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Penticton, Canada
- Brno, Czechia
- Lnáře, Czechia
- Prague, Czechia
- Tallinn, Estonia
- Durango, Mexico
- Guadalajara, Mexico
- Mexico City, Mexico
- Monterrey, Mexico
- Bialystok, Poland
- Lodz, Poland
- Pruszcz Gdański, Poland
- Torun, Poland
- Wroclaw, Poland
- Bucharest, Romania
- Arkhangelsk, Russia
- Gatchina, Russia
- Moscow, Russia
- Roshchino, Russia
- Saint Petersburg, Russia
- Yaroslavl, Russia
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Novi Kneževac, Serbia
- Bratislava, Slovakia
- Zlaté Moravce, Slovakia
- Barcelona, Spain
- Málaga, Spain
- Oviedo, Spain
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kiev, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Oleksandrivka, Ukraine
- Poltava, Ukraine
- Vinnitsa, Ukraine
- Czechia
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Lu AF35700, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
Did this study involve medication?
Yes. The study involved medication, including Lu AF35700.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
